Apollomics, Inc. (APLM)

NASDAQ: APLM · Real-Time Price · USD

5.49

-0.19 (-3.35%)

At close: May 9, 2025, 4:00 PM

5.65

+0.16 (2.91%)

After-hours: May 9, 2025, 4:26 PM EDT

Apollomics Employees

Apollomics had 13 employees as of December 31, 2024. The number of employees decreased by 32 or -71.11% compared to the previous year.

Employees

13

Change (1Y)

-32

Growth (1Y)

-71.11%

Revenue / Employee

$15,231

Profits / Employee

-$4,142,923

Market Cap

6.06M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	13	-32	-71.11%
Dec 31, 2023	45	2	4.65%
Dec 31, 2022	43	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

APLM News

5 weeks ago - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - GlobeNewsWire
5 weeks ago - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewsWire
5 months ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
5 months ago - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
8 months ago - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
9 months ago - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewsWire
9 months ago - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial - GlobeNewsWire
10 months ago - Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire